AlphAIalphai — Financial news for AI agents
National TodayAPR 82 min read$ACRS

Aclaris Therapeutics Earns 'Moderate Buy' Rating from Analysts

Aclaris Therapeutics (NASDAQ:ACRS), a clinical-stage biotech company, has received a consensus 'Moderate Buy' recommendation from analysts, with an average 12-month price target of $9.80 per share. This rating reflects potential in the company's pipeline for dermatological conditions, despite varying analyst recommendations from 'sell' to 'strong buy'. The stock opened at $3.75 on Wednesday, April 8, 2026, with a 52-week range of $1.05 to $4.89.

Original reporting
National Today
Published Apr 8, 2026, 8:56 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Apr 8, 2026, 9:30 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Aclaris Therapeutics Earns 'Moderate Buy' Rating from Analysts — source image
Source · National Today
Decision brief

The 30-second read

$ACRSBullishMed
01

Why it matters

The positive analyst sentiment could lead to increased investor interest and stock appreciation, but clinical and regulatory risks remain.

02

Market read

The news is relevant primarily to biotech investors and those interested in dermatology therapeutics, with potential sector-wide implications.

03

What to watch

Potential delays in clinical trials or regulatory approvals could negatively impact stock performance, which may not be fully reflected in current analyst ratings.

Timing: short-term (next 1-3 months)

Background

Aclaris Therapeutics is a biotech firm focusing on dermatological treatments, currently in clinical development stages.

Company-level read

Ticker impact

$ACRSBullishMedium confidence
Context

The news pertains directly to Aclaris Therapeutics, a biotech company with a 'Moderate Buy' analyst rating.

Expected impact

Moderate upward price movement expected over the next 12 months, with potential for short-term gains.

Evidence & confidence

The analyst consensus and price target indicate positive sentiment; however, the variability in analyst ratings and the company's clinical-stage status introduce uncertainty.

Market effects

Sector

Potential positive impact on biotech and dermatology sectors due to increased investor interest.

Regional

Limited regional impact; primarily relevant to US markets where the company is listed.

Global

Moderate, as biotech stocks can influence global healthcare investment trends.

Counterpoint

What could challenge this read

Some analysts may view the 'Moderate Buy' rating as overly optimistic given the company's clinical-stage status and potential pipeline risks.

Key entities

  • Company
    Aclaris Therapeutics

    A clinical-stage biotech company specializing in dermatology.

Read at source← All news

Related articles

AUG 6
$ACRSMed

Aclaris Therapeutics, Inc. (ACRS): Results of Operations and Financial Condition

Aclaris Therapeutics, Inc. (ACRS) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 acrs-20260806xex99d1.htm EX-99.1 Exhibit 99.1 ​ ​ Aclaris Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate and Clinical Update ​ - Full Top Line Results from Phase 1a SAD/MAD Trial of ATI-052 Validate Potential Best-in-Class Potency Adva

SEC EDGAR 8-K6 min
AUG 8
$RKLBMedAI 8/10

Rocket Lab Just Unveiled a Game-Changing Technology Worth Watching

Rocket Lab (RKLB) said it won a $397 million U.S. Space Force contract to develop, launch, and operate multiple Flatellites for the SB-AMTI program. Flatellites are slimmer, stackable satellites intended to increase deployments per launch and integrate with Rocket Lab’s Neutron rocket. The article cites analyst forecasts for revenue rising from $602M (2025) to $1.7B (2028).

fool.com6 min
AUG 8
$AVAVMedAI 8/10

Bloomberg: US to purchase anti-drone lasers for $400 million

Bloomberg reports the Pentagon will buy laser-based counter-drone systems from AeroVironment Inc. in a deal valued at at least $400 million. The contract is expected to supply the Army with dozens of Locust systems, described as an AI-enabled laser system for tracking and disabling small and medium UAVs. AeroVironment shares rose 8.1% intraday, according to the report.

news.liga.net4 min
AUG 8
$SUNEMedAI 8/10

Pentagon to invest $400m in Australian rare earth mine

Sunrise Energy Metals said the US Pentagon will provide a conditional $400 million loan commitment to develop Syerston, a proposed scandium mine in Fifield, NSW. The project targets Western supply of scandium used in defence and other sectors amid China’s export restrictions. Sunrise also said it has a deal with Lockheed Martin for 25% of output for five years.

bssnews.net4 min
AUG 8
$APLDMedAI 8/10

APLD Stock Rallies After Hours On Massive New $7.5 Billion Hyperscaler Lease: Retail Think Firm Should Be Worth More Than Rival IREN

Applied Digital (APLD) shares rose more than 7% after hours after the company said it surpassed 1 GW of contracted capacity for its AI data centers. It signed a 15-year take-or-pay lease for Polaris Forge 3 with a U.S. investment-grade hyperscaler, valued at about $7.5B base-term contracted revenue and up to $18.2B with renewals. Total contracted lease revenue across four campuses is $31B.

stocktwits.com4 min